Mechanism: Mitochondrial Pyruvate Carrier (MPC) Inhibition
The science behind PP405 stems from a 2017 discovery published in Nature Cell Biology. Researchers found that hair follicle stem cells (HFSCs) are metabolically distinct from other skin cells; they rely on glycolysis and produce high concentrations of lactate. This lactate production is essential for activating the stem cells and restarting the hair growth cycle.
PP405 is a topical inhibitor of the mitochondrial pyruvate carrier (MPC1). By blocking pyruvate from entering the mitochondria, the drug forces the cell to convert that pyruvate into lactate. This sudden surge of lactate triggers the reactivation of dormant stem cells, even in balding areas where follicles have not produced a hair for years.
Clinical Breakthroughs and Evidence
During a week-eight assessment in a Phase 2a trial involving 78 participants, the biological activity of PP405 was quantified with remarkable results.
| Trial Metric | PP405 Result | Placebo Result |
| Hair Density Increase (>20%) | 31% of advanced hair loss subjects | 0% |
| Follicle Reactivation Time | 7 Days (Biopsy evidence) | Not Observed |
| Systemic Absorption | Zero (Blood concentration stable) | N/A |
| Visible Regrowth Onset | 8 Weeks | 6–12 Months (Minoxidil baseline) |
Daniel Gil, PhD, CEO of Pelage, explained the significance: “What’s interesting about the time-lapse photos in our data is that they show hair growing where there was never hair before… [the drug] targets the root cause of dormancy”. Because PP405 is chemically unstable in the blood, it stays exactly where it is applied, eliminating the risk of systemic side effects.
When it will become available and from where: Pelage Pharmaceuticals is launching Phase 3 late-stage studies in 2026. With the backing of $120 million in Series B funding from ARCH Venture Partners and Google Ventures, regulatory approval is anticipated between 2027 and 2029.
How to benefit now: Pelage’s science validates the use of “mitochondria-targeted” topical regimens. Patients can currently access next-generation serums like Bluelene Hair Density Renewal Serum+, powered by methylene blue. This molecule protects HFSCs from oxidative stress and metabolic imbalance, similar to the pathways utilized by PP405, and is available direct-to-consumer as of May 2026.